Boston Scientific Corp
Exchange: NYSESector: HealthcareIndustry: Medical Devices
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
Did you know?
Net income compounded at -7.7% annually over 6 years.
Current Price
$65.69
+1.26%GoodMoat Value
$90.04
37.1% undervaluedProfile
Valuation (TTM)
Market Cap$97.38B
P/E33.60
EV$112.56B
P/B4.02
Shares Out1.48B
P/Sales4.85
Revenue$20.07B
EV/EBITDA20.92
Boston Scientific Corp (BSX) Stock Analysis
GoodMoat Analysis
Boston Scientific is a leading medical device company with a portfolio of life-saving and life-enhancing technologies. It demonstrates several durable competitive advantages, including regulatory barriers and switching costs, and is priced at a favourable discount to its estimated intrinsic value.
Read full analysis
Boston Scientific (BSX) is a global developer and manufacturer of medical devices used in interventional cardiology, rhythm management, endoscopy, and other specialties. Its products are often mission-critical, creating high switching costs for hospitals and physicians. The company operates in a heavily regulated industry, benefiting from significant regulatory barriers that protect its approved products. Applying the GoodMoat framework, BSX likely scores well on criteria such as switching costs, regulatory barriers, and technology leadership, indicating a durable moat. Financially, it shows strong operational health with a 15.9% YoY revenue growth, an 18.0% operating margin, and a manageable debt level. The GoodMoat target price of $90.04 suggests the current price of $69.78 offers a margin of safety of approximately 29%, which falls into the 'Favourable' 20-40% band in the Decision Framework. This indicates the stock is trading at an attractive valuation relative to its estimated intrinsic value. For a value investor, BSX passes the initial Moat & Quality Gate and presents a favourable valuation case, making it a company worth deeper investigation, particularly into the sustainability of its growth drivers and the depth of its technological edge. Analysis based on data as of 2024-05-15.
Market Cap$97.38B
Current Price$65.69
P/E Ratio33.60
Forward P/E—
PEG Ratio1.60
EPS$1.94
Book Value$16.35
P/B Ratio4.02
BSX Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 16.9% FCF growth (CAGR)
Cash vs Debt
Net Debt: 9.5B
Revenue
10.7B
FY19
9.9B
FY20
11.9B
FY21
12.7B
FY22
14.2B
FY23
16.7B
FY24
20.1B
FY25
Net Income
4.7B
FY19
—
FY20
1.0B
FY21
698M
FY22
1.6B
FY23
1.9B
FY24
2.9B
FY25
BSX 52-Week Range
$59.52
$108.14
50-Day MA: $68.92200-Day MA: $91.34
Did you know?
Net income compounded at -7.7% annually over 6 years.
Boston Scientific Corp (BSX) Financial Summary
Boston Scientific Corp (BSX) is a Healthcare company in the Medical Devices industry, listed on NYSE. The stock currently trades at $65.69 with a market capitalization of $97.38B.
Key valuation metrics include a P/E ratio of 33.60, price-to-book ratio of 4.02, and EPS of $1.94. The company reports a profit margin of 14.4% and return on equity of 12.0%.
BSX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $97.38B |
| P/E Ratio | 33.60 |
| EPS | $1.94 |
| P/B Ratio | 4.02 |
| P/S Ratio | 4.85 |
| EV/EBITDA | 20.92 |
| Profit Margin | 14.4% |
| Return on Equity | 12.0% |
| Debt/Equity | 0.47 |
BSX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $10.73B | $4.70B |
| FY20 | $9.91B | $-82.00M |
| FY21 | $11.89B | $1.04B |
| FY22 | $12.68B | $698.00M |
| FY23 | $14.24B | $1.59B |
| FY24 | $16.75B | $1.85B |
| FY25 | $20.07B | $2.90B |
Boston Scientific Corp (BSX) Valuation
Based on GoodMoat's DCF model, Boston Scientific Corp has a fair value estimate of $90.04. At the current price of $65.69, the stock appears 27.0% undervalued relative to our intrinsic value estimate.
BSX Quality Indicators
Boston Scientific Corp maintains a profit margin of 14.4% and an operating margin of 18.0%. Return on equity stands at 12.0%. The current ratio is 1.62. Debt-to-equity ratio is 0.47.
About Boston Scientific Corp
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
BSX Free Cash Flow
Boston Scientific Corp generated $3.66B in trailing twelve-month free cash flow, representing an FCF yield of 3.76%. This moderate FCF yield indicates reasonable cash generation.
BSX Shares Outstanding
Boston Scientific Corp has 1.48 billion shares outstanding at a share price of $65.69, giving it a market capitalization of $97.38B.
BSX Recent Insider Trades
Recent insider transactions at Boston Scientific Corp include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Mahoney Michael F (Chairman, President & CEO) | SELL | 1,200 | $112868.04 |